Your browser doesn't support javascript.
loading
A genomic enhancer signature associates with hepatocellular carcinoma prognosis.
Jeon, Ah-Jung; Anene-Nzelu, Chukwuemeka George; Teo, Yue-Yang; Chong, Shay Lee; Sekar, Karthik; Wu, Lingyan; Chew, Sin-Chi; Chen, Jianbin; Kendarsari, Raden Indah; Lai, Hannah; Ling, Wen Huan; Kaya, Neslihan Arife; Lim, Jia Qi; Chung, Alexander Yaw Fui; Cheow, Peng-Chung; Kam, Juinn Huar; Madhavan, Krishnakumar; Kow, Alfred; Ganpathi, Iyer Shridhar; Lim, Tony Kiat Hon; Leow, Wei-Qiang; Loong, Shihleone; Loh, Tracy Jiezhen; Wan, Wei Keat; Soon, Gwyneth Shook Ting; Pang, Yin Huei; Yoong, Boon Koon; Bee-Lan Ong, Diana; Lim, Jasmine; de Villa, Vanessa H; Dela Cruz, Rouchelle D; Chanwat, Rawisak; Thammasiri, Jidapa; Bonney, Glenn K; Goh, Brian K P; Foo, Roger Sik Yin; Chow, Pierce Kah-Hoe.
Afiliação
  • Jeon AJ; Program in Clinical and Translational Liver Cancer Research, Division of Medical Science, National Cancer Center Singapore, Singapore.
  • Anene-Nzelu CG; Cardiovascular Disease Translational Research Programme, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
  • Teo YY; Montreal Heart Institute, Montreal, Quebec, Canada.
  • Chong SL; Department of Medicine, University of Montreal, Quebec, Canada.
  • Sekar K; Program in Clinical and Translational Liver Cancer Research, Division of Medical Science, National Cancer Center Singapore, Singapore.
  • Wu L; Program in Clinical and Translational Liver Cancer Research, Division of Medical Science, National Cancer Center Singapore, Singapore.
  • Chew SC; Program in Clinical and Translational Liver Cancer Research, Division of Medical Science, National Cancer Center Singapore, Singapore.
  • Chen J; Program in Clinical and Translational Liver Cancer Research, Division of Medical Science, National Cancer Center Singapore, Singapore.
  • Kendarsari RI; Program in Clinical and Translational Liver Cancer Research, Division of Medical Science, National Cancer Center Singapore, Singapore.
  • Lai H; Genome Institute of Singapore, Agency for Science, Technology and Research (A∗STAR), Singapore.
  • Ling WH; Genome Institute of Singapore, Agency for Science, Technology and Research (A∗STAR), Singapore.
  • Kaya NA; Genome Institute of Singapore, Agency for Science, Technology and Research (A∗STAR), Singapore.
  • Lim JQ; Program in Clinical and Translational Liver Cancer Research, Division of Medical Science, National Cancer Center Singapore, Singapore.
  • Chung AYF; Genome Institute of Singapore, Agency for Science, Technology and Research (A∗STAR), Singapore.
  • Cheow PC; Genome Institute of Singapore, Agency for Science, Technology and Research (A∗STAR), Singapore.
  • Kam JH; Department of Hepatopancreatobiliary and Transplant Surgery, National Cancer Centre Singapore and Singapore General Hospital, Singapore.
  • Madhavan K; Academic Clinical Programme for Surgery, Duke-NUS Medical School, Singapore.
  • Kow A; Department of Hepatopancreatobiliary and Transplant Surgery, National Cancer Centre Singapore and Singapore General Hospital, Singapore.
  • Ganpathi IS; Academic Clinical Programme for Surgery, Duke-NUS Medical School, Singapore.
  • Lim TKH; Department of Hepatopancreatobiliary and Transplant Surgery, National Cancer Centre Singapore and Singapore General Hospital, Singapore.
  • Leow WQ; Academic Clinical Programme for Surgery, Duke-NUS Medical School, Singapore.
  • Loong S; Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, University Surgical Cluster, National University Health System, Singapore.
  • Loh TJ; Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, University Surgical Cluster, National University Health System, Singapore.
  • Wan WK; Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, University Surgical Cluster, National University Health System, Singapore.
  • Soon GST; Department of Anatomical Pathology, Singapore General Hospital, Singapore.
  • Pang YH; Department of Anatomical Pathology, Singapore General Hospital, Singapore.
  • Yoong BK; Department of Anatomical Pathology, Singapore General Hospital, Singapore.
  • Bee-Lan Ong D; Department of Anatomical Pathology, Singapore General Hospital, Singapore.
  • Lim J; Department of Anatomical Pathology, Singapore General Hospital, Singapore.
  • de Villa VH; Department of Pathology, National University Hospital, Singapore.
  • Dela Cruz RD; Department of Pathology, National University Hospital, Singapore.
  • Chanwat R; Department of Surgery, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.
  • Thammasiri J; Department of Surgery, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.
  • Bonney GK; Department of Surgery, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.
  • Goh BKP; Department of Surgery and Center for Liver Health and Transplantation, The Medical City, Pasig City, Philippines.
  • Foo RSY; Department of Laboratory Medicine and Pathology, The Medical City, Pasig City, Philippines.
  • Chow PK; Hepato-Pancreato-Biliary Surgery Unit, Department of Surgery, National Cancer Institute, Bangkok, Thailand.
JHEP Rep ; 5(6): 100715, 2023 Jun.
Article em En | MEDLINE | ID: mdl-37168287
ABSTRACT
Background &

Aims:

Lifestyle and environmental-related exposures are important risk factors for hepatocellular carcinoma (HCC), suggesting that epigenetic dysregulation significantly underpins HCC. We profiled 30 surgically resected tumours and the matched adjacent normal tissues to understand the aberrant epigenetic events associated with HCC.

Methods:

We identified tumour differential enhancers and the associated genes by analysing H3K27 acetylation (H3K27ac) chromatin immunoprecipitation sequencing (ChIP-seq) and Hi-C/HiChIP data from the resected tumour samples of 30 patients with early-stage HCC. This epigenome dataset was analysed with previously reported genome and transcriptome data of the overlapping group of patients from the same cohort. We performed patient-specific differential expression testing using multiregion sequencing data to identify genes that undergo both enhancer and gene expression changes. Based on the genes selected, we identified two patient groups and performed a recurrence-free survival analysis.

Results:

We observed large-scale changes in the enhancer distribution between HCC tumours and the adjacent normal samples. Many of the gain-in-tumour enhancers showed corresponding upregulation of the associated genes and vice versa, but much of the enhancer and gene expression changes were patient-specific. A subset of the upregulated genes was activated in a subgroup of patients' tumours. Recurrence-free survival analysis revealed that the patients with a more robust upregulation of those genes showed a worse prognosis.

Conclusions:

We report the genomic enhancer signature associated with differential prognosis in HCC. Findings that cohere with oncofoetal reprogramming in HCC were underpinned by genome-wide enhancer rewiring. Our results present the epigenetic changes in HCC that offer the rational selection of epigenetic-driven gene targets for therapeutic intervention or disease prognostication in HCC. Impact and Implications Lifestyle and environmental-related exposures are the important risk factors of hepatocellular carcinoma (HCC), suggesting that tumour-associated epigenetic dysregulations may significantly underpin HCC. We profiled tumour tissues and their matched normal from 30 patients with early-stage HCC to study the dysregulated epigenetic changes associated with HCC. By also analysing the patients' RNA-seq and clinical data, we found the signature genes - with epigenetic and transcriptomic dysregulation - associated with worse prognosis. Our findings suggest that systemic approaches are needed to consider the surrounding cellular environmental and epigenetic changes in HCC tumours.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article